Exelixis Inc (EXEL)

[kulcek]

Exel is turning to exponential growth.

Last bullish news on exel in previous week:

1. Managment picked up rather shares than money bonuses.

SEC fillings

2. From Roche report - he FDA has granted Fast Track Designation for cobimetinib cobimetinib with Zelboraf.

Roche update of investors

3. New trial - Cabozantinib Phase II against Breast Cancer is starting in October.

Clinical Trials

in pipeline :

Earnings with huge cost savings will be released 4th November in after martket

FDA approval for the cobimetinib with Zelboraf

Potential bid from Roche. Zelboraf's sales are sinking in US and cobimetinib can rapidly increase the sales.

Huge short interest, more than 25% shares of tatal EXEL shares are shorted.